Community Acquired Pneumonia (CAP) Clinical Trial
Official title:
Low Intervention Study of the Effectiveness Of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Against Vaccine Type Pneumococcal Hospitalised Community Acquired Pneumonia (CAP) in Adults 60 Years and Older Using A Test Negative Design Study in A Well-Defined Area of the South of Madrid Region
Low interventional, prospective, multicentre, hospital-based study involving adults 60 years of age and older hospitalised with CAP at participating sites.
PCV13 efficacy for the prevention of vaccine-type community-acquired pneumonia (VT-CAP) and invasive pneumococcal disease (IPD) was established in the Community-acquired Pneumonia Immunization Trial in Adults (CAPITA) aged 65 and older. However, there are still few available real-life effectiveness estimates in adults. The aim of this study is to evaluate the PCV13 vaccine effectiveness (VE) against hospitalised VT-pneumococcal CAP among adults aged ≥60 years in the Region of Madrid (Spain). Determination of the effectiveness of PCV13 to prevent hospitalised vaccine-type (VT)-pneumococcal CAP among adults aged ≥60 years in Madrid will be evaluated using a test-negative design study, overall and among immunocompetent persons only. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00546676 -
Ketek in CAP / AECB in Ambulatory Adult Patients
|
Phase 4 | |
| Completed |
NCT01293435 -
Study Evaluating Management of Patients With Community-Acquired Pneumonia (CAP) or Complicated Skin Infections
|
N/A | |
| Completed |
NCT00809328 -
The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)
|
Phase 3 |